FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2545014037> ?p ?o ?g. }

• W2545014037 endingPage "2735" @default.
• W2545014037 startingPage "2733" @default.
• W2545014037 abstract "Dietary n-3 (ω-3) fatty acids, mainly eicosapentaenoic (C20 : 5n-3, EPA) and docosahexaenoic acids (C22 : 6n-3, DHA) are useful to decrease hypertriglyceridemia in HIV-1-infected patients [1]. These fatty acids are readily incorporated in cell membranes, changing the properties of the phospholipid bilayer [2]. Whether this triggers HIV-1 replication and infectivity remains unexplored, as data are limited to clinical trials conducted in patients under antiretroviral therapy (ART) [3–5], thus precluding the evaluation of any potential effect on viral load. To address this issue, we set up an ex-vivo experiment to test HIV-1 infectivity and replication after inducing a range of ω-3 content in CD4+ T cell membranes resembling to those obtained after dietary supplementation with ω-3 fatty acids. Fatty fish and most fish oil capsules contain both EPA and DHA species at different doses, with DHA usually being the most abundant. The issue of whether all ω-3 species are equal regarding their effects remains elusive. To avoid this caveat, we used DHA as supplemental fatty acid because it is the most abundant ω-3 in cell membranes [6]. CD4+ T cells purified from healthy donors were infected per triplicate with NL4-3 HIV-1 viruses and treated for 7 days with different concentrations of unesterified, albumin-bound DHA (1.25, 2.5, 5, and 10 μmol/l). At the end of the challenge, cell membrane composition was determined by gas chromatography. DHA incorporated into cell membranes in a dose-dependent manner (data not shown), concurring with previous data [7]. Based on previous studies in Western populations, the cardioprotective target level for the ω-3 index (i.e. sum of the proportions of EPA and DHA in red blood cell membranes) has been tentatively set at 8% [8]. In a trial conducted in patients with well controlled HIV-1 infection and hypertriglyceridemia, after 8 weeks of supplementation with 3.4 g/day of ω-3, 60% of patients allocated in the ω-3 arm reached this optimal value [3]. Being aware of some existing methodological differences (mostly regarding to the considered cell type [7] and in-vivo/ex-vivo approaches), in our experiments, such a value was only reached at DHA exposures at least 5 μmol/l (9.6 ± 0.8% in DHA-treated cells versus 3.8 ± 0.2% in untreated condition, P < 0.0001, n = 8; Fig. 1a). We therefore selected this concentration to investigate whether DHA enrichment influences HIV-1 infectivity and viral particle production, assessed by 50% tissue culture infective doses on TZM-bI cells and by p24 ELISA, respectively.Fig. 1: Infectivity and viral replication in medium from HIV-1-infected CD4+ T cells, by absence or presence of DHA in medium for 7 days.(a) DHA + EPA proportion in membrane of CD4+ T cells treated with 5 μmol/l DHA (black) or untreated (grey). Discontinuous line at 8% indicate proposed low-risk cutoff in red blood cells for cardiovascular protection. (b) Infectivity of supernatant after culture in presence or absence of 5 μmol/l DHA (black or grey, respectively), expressed as 50% tissue culture infective dose determined in TZM-bI cells. (c) Number of viral particles (HIV-1 p24 protein quantification) in supernatant after culture in presence or absence of 5 μmol/l DHA (black or grey, respectively). Data expressed as mean ± SD, obtained from three independent biological experiments performed per triplicate. Student's t-test was used to determine significance levels (*P < 0.05; ***P < 0.001). DHA, docosahexaenoic acids; EPA, eicosapentaenoic; TCID50, 50% tissue culture infective dose.We found that DHA induced a significant increase in 50% tissue culture infective doses of the harvested medium (1683 ± 355 in the untreated condition versus 3985 ± 1083 in DHA-treated, P = 0.02, n = 8; Fig. 1b). We ruled out the possibility that the infectivity rise was explained by an overproduction of viral particles, as the HIV-1 particle amount remained essentially unaffected (p24 ELISA, 689 ± 73 ng/ml in the untreated condition versus 717 ± 108 ng/ml in DHA-treated, P = 0.83, n = 9; Fig. 1c). Finally, we explored whether DHA proportion in CD4+ T cell membranes was related to the infectivity of the HIV-1 particles produced by those cells. To that aim, we pooled data from all experiments (three experiments per triplicate adding 5 μmol/l of DHA, and a fourth experiment with all range of tested DHA concentrations). We found a moderate but significant direct correlation between DHA membrane content and HIV-1 infectivity (Pearson's correlation coefficient = 0.39; P = 0.03; n = 30). The mechanisms underlying our findings remain elusive, but studies in experimental models of infection diseases revealed that DHA incorporation can disrupt the physical clustering of lipid rafts and associated proteins, modulating immunity [9,10]. Future research is warranted, in particular studies that focus on the lipid composition of the virus envelope and receptor distribution in cell membranes. Recognizing that our hypothesis can only be directly tested in a randomized clinical trial, our unprecedented data argue against the use of dietary supplements of ω-3 in patients with unsuppressed viral load. This phenomenon could have an impact, but not exclusively, on HIV-1-infected individuals with difficult access to ART, HIV-ART patients with nonresponding ART, or HIV-1-infected undiagnosed individuals. Acknowledgements Conceived and designed the experiments: O.T., S.S.P., M.A. Performed the experiments: O.T., T.E., C.C., T.G. Analyzed the data: O.T., M.A., S.S.P., A.S.V. Wrote the paper: O.T., S.S.P., M.A., A.S.V. Critically revised and subsequently approved the final version: all authors. We thank Dr Emilio Ros and Professor Gilles Mirambeau for their help with the conception of the study, and Dra M. Cofán for assistance with the gas-chromatography analysis. 1Group of Genomics and Pharmacogenomics, AIDS Research Group, Catalan project for the development of an HIV vaccine (HIVACAT), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, Spain; 2Immunopathology and Cellular Immunology, AIDS Research Group, Catalan project for the development of an HIV vaccine (HIVACAT), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, Spain; 3Department of Infectious Diseases, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; 4Centro Nacional de Análisis Genómico, Scientific Park of Barcelona, Barcelona, Spain. French National Center for Scientific Research – Institut de biologie moléculaire et cellulaire, France. The work has been partially supported by the research grants FIS12/00866 from Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Fondo Europeo para el Desarrollo Regional (FEDER); Red de Investigación en SIDA (RIS), ISCIII-RETIC (RD12/0017/0014); and Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN) from ISCIII; AGAUR (SGR-0971) and HIVACAT. M.A. is a researcher from the Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and is supported by the Spanish Health of the ISCIII and the Health Department of the Catalan Government (Generalitat de Catalunya). A.S.V. holds a Miguel Servet I fellowship from the Ministry of Economy and Competitiveness through the ISCIII (CP12/03299). Conflicts of interest There are no conflicts of interest." @default.
• W2545014037 created "2016-11-04" @default.
• W2545014037 creator A5033023982 @default.
• W2545014037 creator A5039630473 @default.
• W2545014037 creator A5046407762 @default.
• W2545014037 creator A5049660116 @default.
• W2545014037 creator A5051735432 @default.
• W2545014037 creator A5055691017 @default.
• W2545014037 creator A5060128405 @default.
• W2545014037 creator A5081672218 @default.
• W2545014037 date "2016-11-13" @default.
• W2545014037 modified "2023-10-18" @default.
• W2545014037 title "ω-3 supplementation in HIV-1-infected individuals with unsuppressed viral load" @default.
• W2545014037 cites W1925234239 @default.
• W2545014037 cites W1982301564 @default.
• W2545014037 cites W2014530834 @default.
• W2545014037 cites W2024698600 @default.
• W2545014037 cites W2027450353 @default.
• W2545014037 cites W2064920341 @default.
• W2545014037 cites W2088140671 @default.
• W2545014037 cites W2094848125 @default.
• W2545014037 cites W2132674183 @default.
• W2545014037 cites W2143659187 @default.
• W2545014037 doi "https://doi.org/10.1097/qad.0000000000001274" @default.
• W2545014037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5106085" @default.
• W2545014037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27782969" @default.
• W2545014037 hasPublicationYear "2016" @default.
• W2545014037 type Work @default.
• W2545014037 sameAs 2545014037 @default.
• W2545014037 citedByCount "1" @default.
• W2545014037 countsByYear W25450140372019 @default.
• W2545014037 crossrefType "journal-article" @default.
• W2545014037 hasAuthorship W2545014037A5033023982 @default.
• W2545014037 hasAuthorship W2545014037A5039630473 @default.
• W2545014037 hasAuthorship W2545014037A5046407762 @default.
• W2545014037 hasAuthorship W2545014037A5049660116 @default.
• W2545014037 hasAuthorship W2545014037A5051735432 @default.
• W2545014037 hasAuthorship W2545014037A5055691017 @default.
• W2545014037 hasAuthorship W2545014037A5060128405 @default.
• W2545014037 hasAuthorship W2545014037A5081672218 @default.
• W2545014037 hasBestOaLocation W25450140372 @default.
• W2545014037 hasConcept C142462285 @default.
• W2545014037 hasConcept C159047783 @default.
• W2545014037 hasConcept C203014093 @default.
• W2545014037 hasConcept C2776452011 @default.
• W2545014037 hasConcept C2779690655 @default.
• W2545014037 hasConcept C2780727368 @default.
• W2545014037 hasConcept C3013748606 @default.
• W2545014037 hasConcept C71924100 @default.
• W2545014037 hasConceptScore W2545014037C142462285 @default.
• W2545014037 hasConceptScore W2545014037C159047783 @default.
• W2545014037 hasConceptScore W2545014037C203014093 @default.
• W2545014037 hasConceptScore W2545014037C2776452011 @default.
• W2545014037 hasConceptScore W2545014037C2779690655 @default.
• W2545014037 hasConceptScore W2545014037C2780727368 @default.
• W2545014037 hasConceptScore W2545014037C3013748606 @default.
• W2545014037 hasConceptScore W2545014037C71924100 @default.
• W2545014037 hasIssue "17" @default.
• W2545014037 hasLocation W25450140371 @default.
• W2545014037 hasLocation W25450140372 @default.
• W2545014037 hasLocation W25450140373 @default.
• W2545014037 hasLocation W25450140374 @default.
• W2545014037 hasOpenAccess W2545014037 @default.
• W2545014037 hasPrimaryLocation W25450140371 @default.
• W2545014037 hasRelatedWork W1983638452 @default.
• W2545014037 hasRelatedWork W2011678344 @default.
• W2545014037 hasRelatedWork W2073516956 @default.
• W2545014037 hasRelatedWork W2090747182 @default.
• W2545014037 hasRelatedWork W2110482783 @default.
• W2545014037 hasRelatedWork W2146530611 @default.
• W2545014037 hasRelatedWork W2295610777 @default.
• W2545014037 hasRelatedWork W2415083001 @default.
• W2545014037 hasRelatedWork W2806991341 @default.
• W2545014037 hasRelatedWork W4242273178 @default.
• W2545014037 hasVolume "30" @default.
• W2545014037 isParatext "false" @default.
• W2545014037 isRetracted "false" @default.
• W2545014037 magId "2545014037" @default.
• W2545014037 workType "article" @default.